Lonza Group stock holds as 2025 sales and profit metrics frame the trade

Lonza Group (CH0013841017) remains a metrics-driven stock story: the company reported CHF 6.6 billion in sales for 2025, core EBITDA of CHF 1.7 billion, and a core EBITDA margin of 25.5% as the latest published figures available here. Those three numbers define the current read-through for Lonza stock far more than any short-term market noise.

Sales and margin set the tone

Lonza said 2025 sales reached CHF 6.6 billion, while core EBITDA came in at CHF 1.7 billion and the core EBITDA margin reached 25.5%. The margin figure is the key comparison point because it shows how much of every sales franc converted into operating profit in the reporting year.

For investors, the combination matters more than the revenue line alone. A business that can hold a 25.5% core EBITDA margin on CHF 6.6 billion of sales signals a different earnings profile than a lower-margin contract manufacturing group.

Profitability still matters most

The 2025 core EBITDA figure of CHF 1.7 billion gives the clearest view of operating strength in the period, and the 25.5% margin adds the missing context. Together, they show how much cash-generating power the company retained after direct operating costs.

That pairing is also the most useful benchmark for assessing valuation later in the year. If sales hold near CHF 6.6 billion while margin stays around 25.5%, the earnings base remains easier to underwrite than a simple top-line number would suggest.

Cell and biologics exposure

Lonza is known for life-science manufacturing, and that business profile is what gives the 2025 sales and margin figures their market relevance. The company’s role across cell and biologics supply chains means operational execution, not only headline revenue, drives investor attention.

In that context, the 2025 numbers point to a company that still had scale and profitability working together. Sales of CHF 6.6 billion and core EBITDA of CHF 1.7 billion are the two figures most likely to anchor how the market evaluates the group’s next reporting step.

Stock level and valuation

The latest verified market value is not included here, so the stock case is framed by the published 2025 operating numbers rather than a live quote. That leaves the focus on profitability, where the 25.5% core EBITDA margin remains the most concise evidence of operating discipline.

Lonza stock therefore reads as a reporting story first and a trading story second. When the next dated market valuation becomes available, it will sit alongside the 2025 base of CHF 6.6 billion sales and CHF 1.7 billion core EBITDA rather than replace them.

Biologics platform

Lonza’s biologics and cell-based manufacturing platform is the most relevant product-and-service lens for the group. It is the operating area that gives meaning to the 2025 margin figure, because contract manufacturing economics depend heavily on utilization, mix and throughput.

London market view

Lonza Group shares are quoted on the SIX Swiss Exchange, and the company’s 2025 report leaves the core investment debate centered on earnings quality. The latest dated market price was not used in this article, so the published sales, core EBITDA and margin figures carry the analysis.

Those figures are: sales of CHF 6.6 billion in 2025, core EBITDA of CHF 1.7 billion in 2025, and a core EBITDA margin of 25.5% in 2025. Together they provide the clearest factual frame for Lonza stock until a fresh market quote is paired with a new company update.